Literature DB >> 33437503

Mortality and glycemic control among patients with acute and chronic myeloid leukemia and diabetes: a case-control study.

Julia E Wiedmeier1, Luke J Mountjoy2,3, Matthew R Buras4, Heidi E Kosiorek4, Kyle E Coppola5, Patricia M Verona6, Curtiss B Cook7, Nina J Karlin2,5.   

Abstract

AIM: We examined the association between diabetes and survival in patients with acute and chronic myeloid leukemia and the association of leukemia with glycemic control. PATIENTS &
METHODS: Patients with leukemia with and without diabetes (2007-2015) were retrospectively identified and matched 1:1 (n = 70 per group). Overall survival was estimated by the Kaplan-Meier method. Hemoglobin A1c and glucose levels the year after leukemia diagnosis were compared by mixed models.
RESULTS: Among 25 of 70 patients with diabetes, mean hemoglobin A1c during the year after leukemia diagnosis was 6.8%. Kaplan-Meier-estimated 3-year survival was 46% for diabetes patients versus 45% for controls (p = 0.79).
CONCLUSION: No associations were found between leukemia, diabetes, survival and glycemic control.
© 2020 Mayo Foundation for Medical Education and Research.

Entities:  

Keywords:  cancer; endocrinology; outcomes research

Year:  2020        PMID: 33437503      PMCID: PMC7787137          DOI: 10.2144/fsoa-2020-0117

Source DB:  PubMed          Journal:  Future Sci OA        ISSN: 2056-5623


  19 in total

1.  Metformin and reduced risk of cancer in diabetic patients.

Authors:  Josie M M Evans; Louise A Donnelly; Alistair M Emslie-Smith; Dario R Alessi; Andrew D Morris
Journal:  BMJ       Date:  2005-04-22

Review 2.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

3.  The global implications of diabetes and cancer.

Authors:  Yuankai Shi; Frank B Hu
Journal:  Lancet       Date:  2014-06-07       Impact factor: 79.321

Review 4.  Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies.

Authors:  Konstantinos K Tsilidis; John C Kasimis; David S Lopez; Evangelia E Ntzani; John P A Ioannidis
Journal:  BMJ       Date:  2015-01-02

5.  A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.

Authors:  Khanh Vu; Naifa Busaidy; Maria E Cabanillas; Marina Konopleva; Stefan Faderl; Deborah A Thomas; Susan O'Brien; Kristine Broglio; Joe Ensor; Carmen Escalante; Michael Andreeff; Hagop Kantarjian; Victor Lavis; Sai-Ching Jim Yeung
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-06-01

6.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.

Authors:  Steven S Coughlin; Eugenia E Calle; Lauren R Teras; Jennifer Petrelli; Michael J Thun
Journal:  Am J Epidemiol       Date:  2004-06-15       Impact factor: 4.897

Review 7.  Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?

Authors:  Michael H Shanik; Yuping Xu; Jan Skrha; Rachel Dankner; Yehiel Zick; Jesse Roth
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

8.  Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.

Authors:  S Scotland; E Saland; N Skuli; F de Toni; H Boutzen; E Micklow; I Sénégas; R Peyraud; L Peyriga; F Théodoro; E Dumon; Y Martineau; G Danet-Desnoyers; F Bono; C Rocher; T Levade; S Manenti; C Junot; J-C Portais; N Alet; C Récher; M A Selak; M Carroll; J-E Sarry
Journal:  Leukemia       Date:  2013-04-09       Impact factor: 11.528

9.  Survival and glycemic control outcomes among patients with coexisting pancreatic cancer and diabetes mellitus.

Authors:  Nina J Karlin; Shailja B Amin; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Curtiss B Cook
Journal:  Future Sci OA       Date:  2018-02-21

10.  Immune-related somatic mutation genes are enriched in PDACs with diabetes.

Authors:  Kaixuan Wang; Wei Zhou; Peng Meng; Peng Wang; Chunhua Zhou; Yao Yao; Shouxin Wu; Yu Wang; Jiangman Zhao; Duowu Zou; Gang Jin
Journal:  Transl Oncol       Date:  2019-06-13       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.